GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (LTS:0LKB) » Definitions » Research & Development

Vanda Pharmaceuticals (LTS:0LKB) Research & Development : $89.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Vanda Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Vanda Pharmaceuticals's Research & Development for the three months ended in Mar. 2025 was $35.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was $89.0 Mil.


Vanda Pharmaceuticals Research & Development Historical Data

The historical data trend for Vanda Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Research & Development Chart

Vanda Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.58 75.36 85.77 76.82 74.43

Vanda Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.15 16.66 16.78 19.84 35.71

Vanda Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $89.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vanda Pharmaceuticals  (LTS:0LKB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Vanda Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines